OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Panetta Partners , an entity associated with Executive Chairman Gabriele Cerrone, acquired 35,000 ordinary shares of OKYO on NASDAQ at $1.00 per share. This transaction has increased Mr. Cerrone's total shareholding to 9,671,570 shares, representing 28.58% of the company's issued share capital.
OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO), un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di terapie oculari innovative, ha annunciato un importante acquisto da parte di un insider. Panetta Partners, un'entità associata al Presidente Esecutivo Gabriele Cerrone, ha acquisito 35.000 azioni ordinarie di OKYO su NASDAQ a $1,00 per azione. Questa transazione ha portato la quota totale di Mr. Cerrone a 9.671.570 azioni, che rappresentano il 28,58% del capitale azionario emesso dalla società.
OKYO Pharma si specializza nei trattamenti per la malattia infiammatoria dell'occhio secco (DED), un mercato da miliardi di dollari, e per il dolore corneale neuropatico (NCP), una condizione oculare attualmente priva di terapie approvate dalla FDA. Questo acquisto da insider potrebbe segnalare fiducia nelle prospettive future della società e negli sviluppi clinici in corso.
OKYO Pharma (NASDAQ: OKYO), una empresa biofarmacéutica en etapa clínica centrada en desarrollar tratamientos oculares innovadores, ha anunciado una importante compra por parte de un insider. Panetta Partners, una entidad asociada con el Presidente Ejecutivo Gabriele Cerrone, adquirió 35.000 acciones ordinarias de OKYO en NASDAQ a $1.00 por acción. Esta transacción ha elevado la participación total de Mr. Cerrone a 9.671.570 acciones, lo que representa el 28.58% del capital social emitido por la compañía.
OKYO Pharma se especializa en tratamientos para la enfermedad inflamatoria del ojo seco (DED), un mercado de miles de millones de dólares, y para el dolor corneal neuropático (NCP), una condición ocular que actualmente carece de terapias aprobadas por la FDA. Esta compra de insider podría indicar confianza en las perspectivas futuras de la empresa y en los desarrollos clínicos en curso.
OKYO Pharma (NASDAQ: OKYO)는 혁신적인 안과 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사로, 중요한 내부자 구매를 발표했습니다. Panetta Partners, 경영 회장 가브리엘레 체로나와 관련된 기관은 NASDAQ에서 OKYO의 35,000주 보통주를 $1.00 per share에 인수했습니다. 이 거래로 인해 Cerrone의 총 주식 보유량은 9,671,570주로 증가했으며, 이는 회사 발행 주식 자본의 28.58%를 차지합니다.
OKYO Pharma는 염증성 안구건조증 (DED), 수십억 달러 규모의 시장 및 신경병증성 각막 통증 (NCP), 현재 FDA의 승인된 치료법이 없는 안과 질환에 대한 치료를 전문으로 하고 있습니다. 이 내부자 구매는 회사의 미래 전망 및 진행 중인 임상 개발에 대한 신뢰를 나타낼 수 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise bio-pharmaceutique en phase clinique axée sur le développement de thérapies oculaires innovantes, a annoncé un achat significatif de la part d'un insider. Panetta Partners, une entité associée au Président Exécutif Gabriele Cerrone, a acquis 35.000 actions ordinaires d'OKYO sur NASDAQ à $1,00 par action. Cette transaction a porté la participation totale de M. Cerrone à 9.671.570 actions, représentant 28,58% du capital social émis par la société.
OKYO Pharma se spécialise dans les traitements de la maladie inflammatoire de l'œil sec (DED), un marché de plusieurs milliards de dollars, et de la douleur cornéenne neuropathique (NCP), une condition oculaire qui ne dispose actuellement d'aucune thérapie approuvée par la FDA. Cet achat d'insider pourrait témoigner d'une confiance dans les perspectives futures de l'entreprise et dans le développement clinique en cours.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Augenheilmittel konzentriert, hat einen bedeutenden Insider-Kauf angekündigt. Panetta Partners, eine mit dem Executive Chairman Gabriele Cerrone verbundene Institution, erwarb 35.000 Stammaktien von OKYO an der NASDAQ zu einem Preis von 1,00 $ pro Aktie. Durch diese Transaktion hat sich der Gesamteigentum von Herrn Cerrone auf 9.671.570 Aktien erhöht, was 28,58% des ausgegebenen Aktienkapitals des Unternehmens entspricht.
OKYO Pharma spezialisiert sich auf Behandlungen für entzündliche Augentrockenheit (DED), einen Markt im Milliardenbereich, und neuropathische Hornhautschmerzen (NCP), eine Augenkrankheit, für die es derzeit keine von der FDA zugelassenen Therapien gibt. Dieser Insider-Kauf könnte Vertrauen in die zukünftigen Perspektiven des Unternehmens und die laufenden klinischen Entwicklungen signalisieren.
- Executive Chairman increases stake, potentially signaling confidence in the company
- Insider now owns 28.58% of the company's issued share capital
- Company focuses on multi-billion-dollar dry eye disease market
- None.
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 35,000 of the Company’s ordinary shares on NASDAQ at a price of US
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
How many shares did Panetta Partners purchase of OKYO Pharma (NASDAQ: OKYO)?
What is Gabriele Cerrone's total shareholding in OKYO Pharma after the recent purchase?
What are the main therapeutic areas OKYO Pharma (NASDAQ: OKYO) focuses on?
What is the significance of the insider purchase for OKYO Pharma (NASDAQ: OKYO)?
